P/E at 36.10 vs Industry's 36.64: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Discount Amid Sector Parity

The current P/E of 36.10 for Sun Pharmaceutical Industries Ltd sits marginally below the Pharmaceuticals & Biotechnology industry average of 36.64. This near parity suggests that the market values the company’s earnings in line with its sector peers, reflecting neither a significant premium nor a discount. Given the large-cap status with a market capitalisation of ₹4,55,381.78 crores, this valuation level implies a degree of confidence in the company’s earnings stability relative to the broader industry. However, the slight discount could also indicate some caution among investors, possibly linked to recent performance trends or sector dynamics — previously rated Buy, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: Mixed Momentum

Examining the stock’s returns across multiple timeframes reveals a divergence in momentum. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 15.52% gain, significantly outperforming the Sensex’s 4.38% loss during the same period. This outperformance extends to longer horizons as well, with three-year and five-year returns of 69.90% and 145.96% respectively, both well ahead of the Sensex’s 19.15% and 38.93% gains. However, the short-term picture is less encouraging. The stock has declined 2.22% over the past month, underperforming the Sensex’s 2.22% rise, and its three-month return of 2.86% slightly trails the Sensex’s 3.09% gain. This suggests some recent headwinds or profit-taking pressure — is this a temporary setback or a sign of shifting fundamentals?

Moving Average Configuration: Mixed Technical Signals

The technical landscape for Sun Pharmaceutical Industries Ltd is characterised by a mixed moving average configuration. The stock price currently trades above its 5-day, 100-day, and 200-day moving averages, signalling some underlying strength and support at these levels. Conversely, it remains below the 20-day and 50-day moving averages, indicating short to medium-term resistance and a potential pause or consolidation phase. This pattern often reflects a recent bounce within a broader sideways or mildly corrective trend — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Relative Performance vs Sensex: Consistent Outperformance Over Longer Terms

When compared with the Sensex, Sun Pharmaceutical Industries Ltd has demonstrated consistent outperformance over the medium to long term. The year-to-date return of 10.36% contrasts sharply with the Sensex’s decline of 8.77%, reinforcing the stock’s resilience amid broader market weakness. Over five and ten years, the stock’s gains of 145.96% and 146.28% respectively, while impressive, lag the Sensex’s 38.93% and 177.07% returns, highlighting a relative strength in the medium term but a more mixed picture over the decade. The one-day and one-week performances are largely inline with the sector and Sensex, with a minor 0.16% decline today against a 0.26% Sensex gain, and a 0.82% weekly rise versus a 0.02% Sensex increase.

Sector Context: Pharmaceuticals & Biotechnology Results Mixed

The Pharmaceuticals & Biotechnology sector has seen 34 stocks declare results recently, with 14 reporting positive outcomes, 15 flat, and 5 negative. This distribution suggests a broadly stable sector environment with pockets of strength and weakness. Sun Pharmaceutical Industries Ltd’s performance and valuation appear to reflect this mixed backdrop, balancing solid long-term gains with some short-term volatility. The sector’s average P/E of 36.64 provides a useful benchmark for assessing the company’s valuation stance within this context.

Rating Context: Previously Rated Buy, Now Reassessed

MarketsMOJO had previously assigned a Buy rating to Sun Pharmaceutical Industries Ltd, with a Mojo Score of 67.0. The rating was updated on 17 Aug 2026, reflecting a reassessment of the company’s fundamentals and market conditions. While the current rating is not disclosed, the data-driven approach highlights the valuation alignment with the sector, the mixed short-term performance, and the technical signals that suggest a nuanced outlook — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced Valuation with Mixed Momentum

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading close to its industry valuation, with a slight discount that may reflect recent short-term challenges. Its long-term performance remains strong relative to the Sensex, but recent months have seen some underperformance and technical resistance. The moving average configuration suggests a tentative recovery within a broader consolidation phase. The sector’s mixed results further contextualise the stock’s performance, while the recent rating reassessment indicates a fresh evaluation of its prospects. Taken together, these factors provide a comprehensive view of the stock’s current standing — what does the current rating imply for investors?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today